Waystar targets low double-digit revenue growth, 40%+ adjusted EBITDA margin in long-term model
Reuters2026/08/26 10:17- Waystar outlined a strategy to push revenue-cycle management toward an “autonomous” model using data and AI-driven workflow automation.
- Market sizing highlighted USD 103.3 billion in total U.S. healthcare RCM spend, including USD 21 billion for RCM software.
- Segment total addressable market for services and software was put at USD 44.1 billion.
- Long-term model targets low double-digit revenue growth, adjusted EBITDA margin above 40%, supported by free cash flow generation.
- Capital allocation priorities include organic investment, debt reduction, share repurchases, disciplined M&A, dividends when appropriate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
